Figure 2

Progression free survival and overall survival. A and B, comparison of progression free survival between HLA-A*2402-mached and -unmatched groups; A, all patients; B, the patients who received the vaccination for more than 12 months. C and D, comparison of overall survival between HLA-A*2402-matched and -unmatched groups; C, all patients; D, patients who received the vaccination for more than 12 months. MST, median survival time; HLA, human leukocyte antigen; M, months; *the weighted log-rank tests with the Harrington-Fleming class of weights were performed and resulted in, ρ = 0, and γ = 0.5, p = 0.186; ρ = 0, and γ = 1, ρ = 0.080; ρ = 0, and γ = 2, ρ = 0.101.